Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-08-19
1999-06-08
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
424427, 424449, 514165, 514359, 514561, 514569, 514579, 5142245, 5142265, 514777, A61K 31715, A61K 4736
Patent
active
059104899
DESCRIPTION:
BRIEF SUMMARY
FIELD OF INVENTION
This invention relates to the treatment of disease and conditions of the skin and exposed tissue. In some embodiments this invention finds application to the treatment of a disease or condition of the skin and exposed tissue including basal cell carcinoma, squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, malignancies and tumours in the skin, genital warts (condyloma acuminata), cervical cancer, HPV (Human Papilloma Virus) including HPV (Human Papilloma Virus) on the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet, actinic keratoses lesions, "liver" spots, fungal lesions, and other such types of lesions, and hair loss on the head of a pregnant women.
This invention also relates to compositions and formulations suitable for use in such treatments, the use of such formulations in such treatments, methods of such treatment, and the delivery of drugs for such treatments.
BACKGROUND OF THE INVENTION
Basal cell carcinoma is presently treated by surgery. Each lesion, together with all surrounding and underlying tissue (dermis, epidermis, and subdermis), is cut out. In some instances, surgery, while necessary for the patient's welfare, puts the patient at risk in some other respect (for example, the removal of a lesion on a patient's temple (resection) may jeopardize the patient's health). Squamous cell tumours are also treated the same way as are other forms of cancer in the skin and exposed tissue. Furthermore, other conditions and diseases of the skin and exposed tissue are treated in the same way or in ways that cause discomfort to the patient, for example melanoma, genital warts, cervical cancer, HPV (Human Papilloma Virus).
Actinic keratoses lesion is dealt with similarly. Liquid nitrogen is also used to remove the lesion.
These diseases and conditions are usually found in the epidermis (at least for the most part, extending into the dermis and upwards through the Stratum Corneum).
Hyaluronic acid is a naturally occurring glycosaminoglycan. Its molecular weight may vary from 50,000 daltons upwards, and it forms highly viscous solutions. As regards the actual molecular weight of hyaluronic acid in natural biological contexts, this is still a matter of much uncertainty; when the molecular weight of hyaluronic acid is to be determined, different values are obtained depending on the assay method employed, and on the source, the isolation method etc. The acid occurs in animal tissue, e.g. spinal fluid, ocular fluid, synovial fluid, cockscombs, skin, and also in some streptococci. Various grades of hyaluronic acid have been obtained. A preparation with an allegedly high degree of purity and alleged to be entirely free from side effects, is a non-inflammatory form described in U.S. Pat. No. 4,141,973; this preparation is said to have a molecular weight exceeding 750,000 dalton, preferably exceeding 1,200,000 dalton and is suggested for therapeutic use in various articular conditions. Applicants believe that hyaluronic acid claimed in this patent is sold under the trade mark Healon.
U.S. Pat. No. 4,801,619 relates to hyaluronic acid, having a molecular weight of about 3.times.10.sup.6 dalton or more, administered intra-articularly which is prone to decrease the proteoglycan content of synovial fluid to almost normal levels. According to this patent, this indicates a positive effect on the proteoglycan metabolism of a joint. According to the patent, this is applicable both to inflammatory conditions and to degeneration caused by treatment with symptomatics, such as corticosteroid preparations. It is thus clear that a sufficiently high molecular weight of the hyaluronic acid is alleged to counteract side effects that might be caused by corticosteroids or other symptomatics producing similar effects. When corticosteroids are applied, the amount of hyaluronic acid in the synovial cavity will, according to the patent, increase substantially and, according to the inventors, their hyaluronic acid p
REFERENCES:
patent: 2583096 (1952-01-01), Hadidian et al.
patent: 3042667 (1962-07-01), Flodin et al.
patent: 3247063 (1966-04-01), Pulver
patent: 3357784 (1967-12-01), Kasper et al.
patent: 3396081 (1968-08-01), Billek et al.
patent: 3436454 (1969-04-01), Nouvel
patent: 3792164 (1974-02-01), Bechtold et al.
patent: 3845201 (1974-10-01), Haddad et al.
patent: 3870791 (1975-03-01), Haddad et al.
patent: 3887703 (1975-06-01), Manoussos et al.
patent: 4003991 (1977-01-01), Krohn et al.
patent: 4045558 (1977-08-01), Smith et al.
patent: 4061722 (1977-12-01), Bodor et al.
patent: 4141973 (1979-02-01), Balazs
patent: 4240163 (1980-12-01), Galin
patent: 4255415 (1981-03-01), Chrai et al.
patent: 4271143 (1981-06-01), Schoenwald et al.
patent: 4272522 (1981-06-01), Balazs
patent: 4280954 (1981-07-01), Yannas et al.
patent: 4303676 (1981-12-01), Balazs
patent: 4328803 (1982-05-01), Pape
patent: 4470975 (1984-09-01), Berger et al.
patent: 4478822 (1984-10-01), Haslam et al.
patent: 4487865 (1984-12-01), Balazs et al.
patent: 4500676 (1985-02-01), Balazs
patent: 4517295 (1985-05-01), Bracke
patent: 4582865 (1986-04-01), Balazs et al.
patent: 4629623 (1986-12-01), Balazs et al.
patent: 4636524 (1987-01-01), Balazs et al.
patent: 4684627 (1987-08-01), LeVeen et al.
patent: 4686288 (1987-08-01), Lormeau et al.
patent: 4711780 (1987-12-01), Fahim
patent: 4713448 (1987-12-01), Balazs et al.
patent: 4716224 (1987-12-01), Sakurai et al.
patent: 4725585 (1988-02-01), Wenge et al.
patent: 4736024 (1988-04-01), Della Valle et al.
patent: 4746504 (1988-05-01), Nimrod et al.
patent: 4755544 (1988-07-01), Makino et al.
patent: 4782046 (1988-11-01), Brown et al.
patent: 4784990 (1988-11-01), Nimrod et al.
patent: 4784991 (1988-11-01), Nimrod et al.
patent: 4795741 (1989-01-01), Leshchiner et al.
patent: 4801619 (1989-01-01), Lindblad
patent: 4804537 (1989-02-01), Bergman et al.
patent: 4808576 (1989-02-01), Schultz et al.
patent: 4814175 (1989-03-01), Tack et al.
patent: 4820732 (1989-04-01), Shell et al.
patent: 4840941 (1989-06-01), Ueno et al.
patent: 4851521 (1989-07-01), della Valle et al.
patent: 4853224 (1989-08-01), Wong
patent: 4853226 (1989-08-01), Machida et al.
patent: 4855134 (1989-08-01), Yamahira et al.
patent: 4863907 (1989-09-01), Sakurai et al.
patent: 4877619 (1989-10-01), Richer
patent: 4879282 (1989-11-01), Saliba, Jr.
patent: 4912093 (1990-03-01), Michaeli
patent: 4913898 (1990-04-01), Altobelli et al.
patent: 4937254 (1990-06-01), Sheffield et al.
patent: 4937270 (1990-06-01), Hamilton et al.
patent: 4944941 (1990-07-01), Ammann
patent: 4957744 (1990-09-01), della Valle
patent: 4963666 (1990-10-01), Malson
patent: 4965353 (1990-10-01), della Valle
patent: 5092841 (1992-03-01), Spears
patent: 5095037 (1992-03-01), Iwamitsu
patent: 5116331 (1992-05-01), della Valle
patent: 5116864 (1992-05-01), March et al.
patent: 5202431 (1993-04-01), della Valle
patent: 5236906 (1993-08-01), Yamamoto
patent: 5442053 (1995-08-01), della Valle et al.
Abatangelo G, Martelli M, Vecchia P.
Healing of hyaluronic acid-enriched wounds: Histological observations. J. Surgical Research 1983; 35: 410-416.
Abatangelo G, Corvito R, et al. Cell detachment mediated by hyaluronic acid. Exp. Cell Res. 1982; 137: 73-78.
Adams JB. Steroid hormones and breast cancer. Dissertation Abstracts International 1981; 42(4): 1425B.
Ahlgren T, Jarstrand C. Hyaluronic acid enhances phagocytosis of human monocytes vitro. J Clinical Immunology 1984; 4(3): 246-249.
Alaverdyan MI, Ter-Avetisyan AT. Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemai. Bulletin of Experimental Biology and Medicine 1967; 64(9): 967-969.
Alexander P. Ageing skin: Remedial measures. Manuf. Chemist 1985; Oct.: 35, 37, 39.
Altman RD, Kapila P, Dean DD, Howell DS. Future therapeutic trends in osteoarthritis. Scand, J. Rheumatology 1989; Suppl. 77: 37-42.
Ambroggio G, Barberis ML. Trattamento di lesioni cutanee ad andamento cronico con acido ialuronico. Minerva Chirurgica 196
Asculai Samuel Simon
Falk Rudolf Edgar
Hughes Ivor M.
Hughes Neil H.
Hyal Pharmaceutical Corporation
Kishore Gollamudi S.
Sarkis Marcelo K.
LandOfFree
Topical composition containing hyaluronic acid and NSAIDS does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical composition containing hyaluronic acid and NSAIDS, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical composition containing hyaluronic acid and NSAIDS will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1683369